Chromatographic method for determination of glycated proteinaceous species in blood

• US 5,843,788 A
• Filed: 09/21/1994
• Issued: 12/01/1998
• Est. Priority Date: 12/05/1988
• Status: Expired due to Term

• Current Assignee: Primus Corporation (MiCo IVD Holdings, LLC)
• Original Assignee: Clinical HPLC, Inc.
• Inventors: Noffsinger, Jimmie K., Rexroad, James H. Jr., Wawrzinek, Claus-Peter, Teeman, Bonnie A.
• Primary Examiner(s): LUDLOW, JAN M
• Application Number:
  US08/309,795
• Time in Patent Office: 1,532 Days
• Field of Search: 436/66, 436/67, 436/86-88, 436/161, 530/413, 530/414, 210/198.2, 210/656, 210/660, 210/661
• US Class Current: 436/161
• CPC Class Codes: G01N 2030/342 fluid composition fixed during analysis
• CPC Class Codes: G01N 2030/626 calibration, baseline
• CPC Class Codes: G01N 2030/8804 automated systems
• CPC Class Codes: G01N 2030/8813 biological materials
• CPC Class Codes: G01N 2030/8831 involving peptides or proteins
• CPC Class Codes: G01N 30/74 Optical detectors measurement of intensity, velocity, spectral content, polarisation, or phase of infrared, visible or ultraviolet light G01J
• CPC Class Codes: G01N 30/88 Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
• CPC Class Codes: G01N 33/68 involving proteins, peptides or amino acids involving lipoproteins G01N33/92
• CPC Class Codes: G01N 33/6842 Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
• CPC Class Codes: G01N 33/723 Glycosylated haemoglobin

Abstract

A method for continuous separation and analysis of glycated and non-glycated proteins in a blood sample by HPLC using a phenylboronic acid resin and a buffered polyol as eluent.

Claims

1. A method of analyzing a liquid sample containing both glycated and nonglycated blood protein fractions using high pressure liquid chromatographic separation techniques, said method comprising the steps of:

providing a high pressure liquid chromatographic column including therein synthetic resin polymer particles having a diameter of from about 3-20 microns with a phenylboronic acid covalently coupled to said polymer particles;

contacting said column with said liquid sample having a volume of from 0.01-0.125 μ

L of red blood cells or from about 0.2-2.5 μ

L of serum or plasma, and with a transport solution for said nonglycated protein fraction, said transport solution containing a buffering agent and a salt, causing said glycated protein fraction to complex with said phenylboronic acid, and continuously separating said transport solution and nonglycated protein fraction from the column as a first analyte;

thereafter contacting said column and complexed glycated proteins with an eluant for separating the glycated proteins from the column, said eluant containing mannitol and a salt, and continuously separating said eluant and said separated glycated proteins from the column as a second analyte

said contacting steps being carried out at a superatmospheric column pressure; and

continuously spectrophotometrically analyzing each of said first and second analytes in serial order using light of a desired wavelength, said spectrophotometric analysis being carried out without blanking of the spectrophotometer with said eluant,

the spectrophotometric analysis of said first and second analytes yielding data, which if graphically plotted, would present a pair of separate, single, sharp integratable peaks respectively corresponding to the quantities of said first and second analytes present in said sample,

said transport solution and eluant being spectrophotometrically balanced such that, in the quantitative high pressure liquid chromatographic determination of glycated protein in a 0.5 ul. liquid test sample containing 6 to 8 g./dl. of total protein and a glycated protein content of the test sample, said determination being carried out at said desired wavelength, the calculated signal to noise ratio is equal to or greater than about 20, where the signal is the height of the absorbance peak produced by the glycated fraction of the test sample, and the noise is the greatest distance of deviation observed when a blank sample of the transport solution is measured at said desired wavelength and at otherwise identical test conditions, both said height and distance being measured relative to an idealized baseline established by the absorbance at said desired wavelength of the transport solution.

2. The method of claim 1, said sample containing glycated and nonglycated hemoglobin fractions, said light having a wavelength of about 412-415 nm.

3. The method of claim 1, said sample containing glycated and nonglycated serum protein fractions, said light having a wavelength of about 280 nm.

4. The method of claim 1, including the step of contacting said column with said transport solution prior to initial contact between the column and sample.

5. A method of continuously and sequentially analyzing a plurality of liquid samples each containing both glycated and nonglycated blood protein fractions in respective blood-derived analytes using high pressure liquid chromatographic separation techniques, said method comprising the steps of:

(a) providing a high pressure liquid chromatographic column comprising synthetic resin polymer particles with a phenylboronic acid covalently coupled to the polymer particles;

(b) contacting said column with a respective small liquid sample containing from 3.38-181.3 micrograms of blood-derived analyte and with a transport solution for said nonglycated protein fraction, said transport solution containing a buffering agent and a salt, causing said glycated protein fraction of said respective liquid sample to complex with said phenylboronic acid, and continuously separating said transport solution and the nonglycated protein fraction of said respective liquid sample from the column as a first analyzable mixture;

(c) thereafter contacting said column and complexed glycated proteins with eluant means for separating the glycated proteins from the column and allowing the time period of step (g), and continuously separating said eluant and said separated glycated proteins from the column as a second analyzable mixture,

(d) removing eluant species from said column using a liquid mobile phase and reequilibrating the column,

(e) said contacting steps being carried out at superatmospheric column pressure;

(f) continuously spectrophotometrically analyzing each of said first and second analyzable mixtures in serial order using light of a desired wavelength; and

(g) repeating steps (b)-(f), inclusive, to provide an analysis of each of said plurality of samples, with the total time between successive initial contacts of respective liquid samples with said column being no greater than about 8 minutes.

6. The method of claim 5, said eluant means containing mannitol and a salt.

7. The method of claim 5, said eluant species-removing step comprising the step of passing a liquid mobile phase means different than said transport solution through said column to remove said eluant species, and thereafter reequilibrating said column with said transport solution.